List of Chapters/Sections(Table Of Content)
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Biosimilars Revenue
1.4 Market Analysis by Type
1.4.1 Global Biosimilars Market Size Growth Rate by Type: 2021 VS 2027
1.4.2 Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon)
1.4.3 Recombinant Glycosylated Proteins
1.5 Market by Application
1.5.1 Global Biosimilars Market Share by Application: 2022-2027
1.5.2 Oncology
1.5.3 Blood Disorders
1.5.4 Growth Hormonal Deficiency
1.5.5 Chronic and Autoimmune Disorders
1.6 Study Objectives
1.7 Years Considered
1.8 Overview of Global Biosimilars Market
1.8.1 Global Biosimilars Market Status and Outlook (2016-2027)
1.8.2 North America
1.8.3 East Asia
1.8.4 Europe
1.8.5 South Asia
1.8.6 Southeast Asia
1.8.7 Middle East
1.8.8 Africa
1.8.9 Oceania
1.8.10 South America
1.8.11 Rest of the World
2 Market Competition by Manufacturers
2.1 Global Biosimilars Production Capacity Market Share by Manufacturers (2016-2021)
2.2 Global Biosimilars Revenue Market Share by Manufacturers (2016-2021)
2.3 Global Biosimilars Average Price by Manufacturers (2016-2021)
2.4 Manufacturers Biosimilars Production Sites, Area Served, Product Type
3 Sales by Region
3.1 Global Biosimilars Sales Volume Market Share by Region (2016-2021)
3.2 Global Biosimilars Sales Revenue Market Share by Region (2016-2021)
3.3 North America Biosimilars Sales Volume
3.3.1 North America Biosimilars Sales Volume Growth Rate (2016-2021)
3.3.2 North America Biosimilars Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.4 East Asia Biosimilars Sales Volume
3.4.1 East Asia Biosimilars Sales Volume Growth Rate (2016-2021)
3.4.2 East Asia Biosimilars Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.5 Europe Biosimilars Sales Volume (2016-2021)
3.5.1 Europe Biosimilars Sales Volume Growth Rate (2016-2021)
3.5.2 Europe Biosimilars Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.6 South Asia Biosimilars Sales Volume (2016-2021)
3.6.1 South Asia Biosimilars Sales Volume Growth Rate (2016-2021)
3.6.2 South Asia Biosimilars Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.7 Southeast Asia Biosimilars Sales Volume (2016-2021)
3.7.1 Southeast Asia Biosimilars Sales Volume Growth Rate (2016-2021)
3.7.2 Southeast Asia Biosimilars Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.8 Middle East Biosimilars Sales Volume (2016-2021)
3.8.1 Middle East Biosimilars Sales Volume Growth Rate (2016-2021)
3.8.2 Middle East Biosimilars Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.9 Africa Biosimilars Sales Volume (2016-2021)
3.9.1 Africa Biosimilars Sales Volume Growth Rate (2016-2021)
3.9.2 Africa Biosimilars Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.10 Oceania Biosimilars Sales Volume (2016-2021)
3.10.1 Oceania Biosimilars Sales Volume Growth Rate (2016-2021)
3.10.2 Oceania Biosimilars Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.11 South America Biosimilars Sales Volume (2016-2021)
3.11.1 South America Biosimilars Sales Volume Growth Rate (2016-2021)
3.11.2 South America Biosimilars Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.12 Rest of the World Biosimilars Sales Volume (2016-2021)
3.12.1 Rest of the World Biosimilars Sales Volume Growth Rate (2016-2021)
3.12.2 Rest of the World Biosimilars Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
4 North America
4.1 North America Biosimilars Consumption by Countries
4.2 United States
4.3 Canada
4.4 Mexico
5 East Asia
5.1 East Asia Biosimilars Consumption by Countries
5.2 China
5.3 Japan
5.4 South Korea
6 Europe
6.1 Europe Biosimilars Consumption by Countries
6.2 Germany
6.3 United Kingdom
6.4 France
6.5 Italy
6.6 Russia
6.7 Spain
6.8 Netherlands
6.9 Switzerland
6.10 Poland
7 South Asia
7.1 South Asia Biosimilars Consumption by Countries
7.2 India
7.3 Pakistan
7.4 Bangladesh
8 Southeast Asia
8.1 Southeast Asia Biosimilars Consumption by Countries
8.2 Indonesia
8.3 Thailand
8.4 Singapore
8.5 Malaysia
8.6 Philippines
8.7 Vietnam
8.8 Myanmar
9 Middle East
9.1 Middle East Biosimilars Consumption by Countries
9.2 Turkey
9.3 Saudi Arabia
9.4 Iran
9.5 United Arab Emirates
9.6 Israel
9.7 Iraq
9.8 Qatar
9.9 Kuwait
9.10 Oman
10 Africa
10.1 Africa Biosimilars Consumption by Countries
10.2 Nigeria
10.3 South Africa
10.4 Egypt
10.5 Algeria
10.6 Morocco
11 Oceania
11.1 Oceania Biosimilars Consumption by Countries
11.2 Australia
11.3 New Zealand
12 South America
12.1 South America Biosimilars Consumption by Countries
12.2 Brazil
12.3 Argentina
12.4 Columbia
12.5 Chile
12.6 Venezuela
12.7 Peru
12.8 Puerto Rico
12.9 Ecuador
13 Rest of the World
13.1 Rest of the World Biosimilars Consumption by Countries
13.2 Kazakhstan
14 Sales Volume, Sales Revenue, Sales Price Trend by Type
14.1 Global Biosimilars Sales Volume Market Share by Type (2016-2021)
14.2 Global Biosimilars Sales Revenue Market Share by Type (2016-2021)
14.3 Global Biosimilars Sales Price by Type (2016-2021)
15 Consumption Analysis by Application
15.1 Global Biosimilars Consumption Volume by Application (2016-2021)
15.2 Global Biosimilars Consumption Value by Application (2016-2021)
16 Company Profiles and Key Figures in Biosimilars Business
16.1 Pfizer
16.1.1 Pfizer Company Profile
16.1.2 Pfizer Biosimilars Product Specification
16.1.3 Pfizer Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.2 Novartis
16.2.1 Novartis Company Profile
16.2.2 Novartis Biosimilars Product Specification
16.2.3 Novartis Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.3 Biocon
16.3.1 Biocon Company Profile
16.3.2 Biocon Biosimilars Product Specification
16.3.3 Biocon Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.4 Biogen
16.4.1 Biogen Company Profile
16.4.2 Biogen Biosimilars Product Specification
16.4.3 Biogen Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.5 Fresenius Kabi AG
16.5.1 Fresenius Kabi AG Company Profile
16.5.2 Fresenius Kabi AG Biosimilars Product Specification
16.5.3 Fresenius Kabi AG Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.6 Boehringer Ingelheim
16.6.1 Boehringer Ingelheim Company Profile
16.6.2 Boehringer Ingelheim Biosimilars Product Specification
16.6.3 Boehringer Ingelheim Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.7 Merck KgaA
16.7.1 Merck KgaA Company Profile
16.7.2 Merck KgaA Biosimilars Product Specification
16.7.3 Merck KgaA Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.8 Mylan
16.8.1 Mylan Company Profile
16.8.2 Mylan Biosimilars Product Specification
16.8.3 Mylan Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.9 Eli Lilly
16.9.1 Eli Lilly Company Profile
16.9.2 Eli Lilly Biosimilars Product Specification
16.9.3 Eli Lilly Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.10 Teva Pharmaceutical
16.10.1 Teva Pharmaceutical Company Profile
16.10.2 Teva Pharmaceutical Biosimilars Product Specification
16.10.3 Teva Pharmaceutical Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.11 Dr. Reddys Laboratories
16.11.1 Dr. Reddys Laboratories Company Profile
16.11.2 Dr. Reddys Laboratories Biosimilars Product Specification
16.11.3 Dr. Reddys Laboratories Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.12 Amgen
16.12.1 Amgen Company Profile
16.12.2 Amgen Biosimilars Product Specification
16.12.3 Amgen Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.13 Celltrion
16.13.1 Celltrion Company Profile
16.13.2 Celltrion Biosimilars Product Specification
16.13.3 Celltrion Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.14 Samsung Biologics
16.14.1 Samsung Biologics Company Profile
16.14.2 Samsung Biologics Biosimilars Product Specification
16.14.3 Samsung Biologics Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.15 Roche
16.15.1 Roche Company Profile
16.15.2 Roche Biosimilars Product Specification
16.15.3 Roche Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.16 Probiomed
16.16.1 Probiomed Company Profile
16.16.2 Probiomed Biosimilars Product Specification
16.16.3 Probiomed Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.17 Apotex
16.17.1 Apotex Company Profile
16.17.2 Apotex Biosimilars Product Specification
16.17.3 Apotex Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.18 Chong Kun Dang
16.18.1 Chong Kun Dang Company Profile
16.18.2 Chong Kun Dang Biosimilars Product Specification
16.18.3 Chong Kun Dang Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.19 JCR Pharmaceuticals
16.19.1 JCR Pharmaceuticals Company Profile
16.19.2 JCR Pharmaceuticals Biosimilars Product Specification
16.19.3 JCR Pharmaceuticals Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.20 Gan & Lee Pharmaceuticals
16.20.1 Gan & Lee Pharmaceuticals Company Profile
16.20.2 Gan & Lee Pharmaceuticals Biosimilars Product Specification
16.20.3 Gan & Lee Pharmaceuticals Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.21 Gedeon Richter
16.21.1 Gedeon Richter Company Profile
16.21.2 Gedeon Richter Biosimilars Product Specification
16.21.3 Gedeon Richter Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.22 Biocad
16.22.1 Biocad Company Profile
16.22.2 Biocad Biosimilars Product Specification
16.22.3 Biocad Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.23 Coherus Bioscience
16.23.1 Coherus Bioscience Company Profile
16.23.2 Coherus Bioscience Biosimilars Product Specification
16.23.3 Coherus Bioscience Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.24 Stada Arzneimittel AG
16.24.1 Stada Arzneimittel AG Company Profile
16.24.2 Stada Arzneimittel AG Biosimilars Product Specification
16.24.3 Stada Arzneimittel AG Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
17 Biosimilars Manufacturing Cost Analysis
17.1 Biosimilars Key Raw Materials Analysis
17.1.1 Key Raw Materials
17.2 Proportion of Manufacturing Cost Structure
17.3 Manufacturing Process Analysis of Biosimilars
17.4 Biosimilars Industrial Chain Analysis
18 Marketing Channel, Distributors and Customers
18.1 Marketing Channel
18.2 Biosimilars Distributors List
18.3 Biosimilars Customers
19 Market Dynamics
19.1 Market Trends
19.2 Opportunities and Drivers
19.3 Challenges
19.4 Porter's Five Forces Analysis
20 Production and Supply Forecast
20.1 Global Forecasted Production of Biosimilars (2022-2027)
20.2 Global Forecasted Revenue of Biosimilars (2022-2027)
20.3 Global Forecasted Price of Biosimilars (2016-2027)
20.4 Global Forecasted Production of Biosimilars by Region (2022-2027)
20.4.1 North America Biosimilars Production, Revenue Forecast (2022-2027)
20.4.2 East Asia Biosimilars Production, Revenue Forecast (2022-2027)
20.4.3 Europe Biosimilars Production, Revenue Forecast (2022-2027)
20.4.4 South Asia Biosimilars Production, Revenue Forecast (2022-2027)
20.4.5 Southeast Asia Biosimilars Production, Revenue Forecast (2022-2027)
20.4.6 Middle East Biosimilars Production, Revenue Forecast (2022-2027)
20.4.7 Africa Biosimilars Production, Revenue Forecast (2022-2027)
20.4.8 Oceania Biosimilars Production, Revenue Forecast (2022-2027)
20.4.9 South America Biosimilars Production, Revenue Forecast (2022-2027)
20.4.10 Rest of the World Biosimilars Production, Revenue Forecast (2022-2027)
20.5 Forecast by Type and by Application (2022-2027)
20.5.1 Global Sales Volume, Sales Revenue and Sales Price Forecast by Type (2022-2027)
20.5.2 Global Forecasted Consumption of Biosimilars by Application (2022-2027)
21 Consumption and Demand Forecast
21.1 North America Forecasted Consumption of Biosimilars by Country
21.2 East Asia Market Forecasted Consumption of Biosimilars by Country
21.3 Europe Market Forecasted Consumption of Biosimilars by Countriy
21.4 South Asia Forecasted Consumption of Biosimilars by Country
21.5 Southeast Asia Forecasted Consumption of Biosimilars by Country
21.6 Middle East Forecasted Consumption of Biosimilars by Country
21.7 Africa Forecasted Consumption of Biosimilars by Country
21.8 Oceania Forecasted Consumption of Biosimilars by Country
21.9 South America Forecasted Consumption of Biosimilars by Country
21.10 Rest of the world Forecasted Consumption of Biosimilars by Country
22 Research Findings and Conclusion
23 Methodology and Data Source
23.1 Methodology/Research Approach
23.1.1 Research Programs/Design
23.1.2 Market Size Estimation
23.1.3 Market Breakdown and Data Triangulation
23.2 Data Source
23.2.1 Secondary Sources
23.2.2 Primary Sources
23.3 Disclaimer
